

What is claimed is:

1. A method for modulating metabolism of pathogenic Mycoplasma bacteria comprising the step of contacting pathogenic Mycoplasma bacteria with an antibacterially effective amount of a composition comprising a gemifloxacin compound, or antibacterially effective derivatives thereof.
2. The method of claim 1 wherein said pathogenic Mycoplasma bacteria is selected from the group consisting of:
Mycoplasma pneumoniae, *M. hominis*, *M. fermentans*, *M. genitalium*, *M. penetrans* and *Ureaplasma urealyticum*.
3. A method of treating or preventing a bacterial infection by pathogenic Mycoplasma bacteria comprising the step of administering an antibacterially effective amount of a composition comprising a gemifloxacin compound to a mammal suspected of having or being at risk of having an infection with pathogenic Mycoplasma bacteria.
4. The method of claim 3 wherein said pathogenic Mycoplasma bacteria is selected from the group consisting of:
Mycoplasma pneumoniae, *M. hominis*, *M. fermentans*, *M. genitalium*, *M. penetrans* and *Ureaplasma urealyticum*.
5. The method of claim 1 wherein said modulating metabolism is inhibiting growth of said bacteria.
6. The method of claim 1 wherein said modulating metabolism is killing said bacteria.
7. The method of claim 1 wherein said contacting said bacteria comprises the further step of introducing said composition into a mammal.
8. The method of claim 3 wherein said mammal is a human.
9. The method of claim 7 wherein said mammal is a human.
10. The method of claim 1 wherein said bacteria is selected from the group consisting of: *Mycoplasma pneumoniae*, *M. hominis*, *M. fermentans*, *M. genitalium*, *M. penetrans* and *Ureaplasma urealyticum*.
11. The method of claim 1 wherein said bacteria is selected from the group consisting of: *Mycoplasma pneumoniae*, *M. hominis*, *M. fermentans*, *M. genitalium*, *M. penetrans* and *Ureaplasma urealyticum*.